The Epigenetic Regulatory Role of P-element Induced Wimpy Testis (Piwi) Interacting RNA-823 (piR-823) in Ovarian Cancer Progression

NCT06320418 | Active Not Recruiting

• 1 other identifier: RHDIRB2020110301REC#196
• Study Type: observational
• Target: 56
• Locations: 1 country
• Sites: 1

Brief Summary

Ovarian cancer (OC) has one of the highest mortality rates for female malignant tumors, attributed to advanced cancer stages upon diagnosis as well as a high recurrence rate. Piwi-interacting RNA-823 (piR-823) is a single-stranded non-protein coding RNA (ncRNA) star molecule in epigenetics research. Extensive cellular regulatory functions and aberrant expression of piR-823 have been implicated in carcinogenesis. Therefore, the findings of piwi-ncRNA dysregulated-expression in OC Egyptian female patients' cohort could be employed as a potential novel mechanism for OC precision, a step toward ncRNA-precision

Conditions

Ovarian Cancer

Keywords

piR-823, Ovarian cancer, DNA methylation

Outcome Measures

Primary Outcomes (1)

• Association of piR-823 expression with ovarian cancer progression

  Investigating the expression of piR-823 in ovarian cancer tissue samples using qRT-PCR.

  18 months

Study Arms (2)

Patients group

A total of 39 female patients in their age range (13-75 years) diagnosed with primary malignant ovarian tumors were enrolled in the study. OC patients were a treatment-naïve Egyptian patients' cohort admitted to the Gynecology and Obstetrics Department or the Oncology Dept., Ain Shams University Hospitals, Cairo, Egypt. Ovarian cancer tissue samples were collected during surgical resection and confirmed by postoperative pathological examinations.

Control group

A total of 17 normal ovarian tissue samples were collected from patients with benign uterine diseases, such as myoma, who underwent uterine and ovarian resection. The control's age range is 45-62 years

Eligibility Criteria

• Gender Eligibility Details: study of ovarian cancer
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The patient enrolled in the study if they met the inclusion criteria and, after giving their approval for participation in the study, signed the informed consent.

You may qualify if:

• Newly diagnosed patients
• Untreated cases of patients
• Histopathologically confirmed OC patients

You may not qualify if:

• Individuals receiving chemotherapy, and radiation
• Patients with a history of other cancers other than ovarian cancer
• Individuals with inadequate data or missing histopathological diagnoses.

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Faculty of Pharmacy, Ain Shams University, Advanced Biochemistry Research Lab

Cairo, 11566, Egypt

Location

Related Publications (1)

• References [1] R. Jiang et al., "Inhibition of long non-coding RNA XIST upregulates microRNA-149-3p to repress OC cell progression," Cell Death Dis., vol. 12, no. 2, p. 145, Feb. 2021, doi: 10.1038/s41419-020-03358-0. [3] E. Lee, N. A. Lokman, et al. "A Comprehensive Molecular and Clinical Analysis of the piRNA Pathway Genes in OC," Cancers (Basel)., vol. 13, no. 1, p. 4, Dec. 2020, doi: 10.3390/cancers13010004. [4] K. Wang, T. Wang, X. Gao, X. Chen, F. Wang, and L. Zhou, "Emerging functions of piwi-interacting RNAs in diseases," J. Cell. Mol. Med., vol. 25, no. 11, pp. 4893-4901, Jun. 2021, doi: 10.1111/jcmm.16466. [5] G. Singh, J. Roy, P. Rout, and B. Mallick, "Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory networks in epithelial OCs," PLoS One, vol. 13, no. 1, p. e0190485, Jan. 2018, doi: 10.1371/journal.pone.0190485. [6] N. A. Sabbah et al., "piRNA-823 Is a Unique Potential Diagnostic Non-Invasive Biomarker in Colorectal Cancer Patients," Genes (Basel)., vol. 12, no. 4, p. 598, Apr. 2021, doi: 10.3390/genes12040598. [7] J.-F. Su et al., "piR-823 demonstrates tumor oncogenic activity in esophageal squamous cell carcinoma through DNA methylation induction via DNA methyltransferase 3B," Pathol. - Res. Pract., vol. 216, no. 4, p. 152848, Apr. 2020, doi: 10.1016/j.prp.2020.152848.

  BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Ovarian fresh tissue samples were collected from the controls, and OC patients underwent surgical resection at the Department of Obstetrics and Gynecology, Ain Shams University. All resected tissue samples were stored at -20°C after adding RNA Stabilization Reagent

MeSH Terms

Conditions

Ovarian Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders

Study Officials

• Nadia Hamdy, PhD

  faculty of pharmacy Ain Shams university

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: professor of Biochemistry and molecular biology

Study Record Dates

• First Submitted: February 22, 2024
• First Posted: March 20, 2024
• Study Start: June 15, 2022
• Primary Completion: December 10, 2023
• Study Completion: June 1, 2024
• Last Updated: March 20, 2024

Record last verified: 2024-03

Locations

EG (1)